Mahallawi Waleed H, Ibrahim Nadir A, Mumena Walaa A
Medical Laboratory Technology Department, College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia.
Duke Central Automated Laboratory, Duke University, Hudson Bldg, DCAL, Rm 1520, 2351, Erwin Rd, Durham, NC, USA.
Saudi J Biol Sci. 2023 Oct;30(10):103788. doi: 10.1016/j.sjbs.2023.103788. Epub 2023 Aug 23.
Hepatitis B virus (HBV) infection is a worldwide health problem. We aimed in this study to investigate the humoral immune response derived to HBV vaccine following completing the vaccine series in Madinah. Two hundred and two Saudi hemodialysis (HD) patients were included in this cross-sectional study. Mean concentration of Hepatitis B surface antibody (anti-HBs) was significantly higher among patients who received the vaccination twice compared to patients who received the vaccination only after starting hemodialysis (252 ± 489 mIU/mL vs. 144 ± 327 mIU/mL, respectively, = 0.008). Almost half of the study sample were non-protected and showed anti-HBs concentration < 10 mlU/mL. In contrast, 20.3% (n = 41) were identified as poor responders (10-100 mlU/mL) and only 28.2% (n = 57) were identified as good responders (10-100 mlU/mL). However, the latter two groups were accounted as protected (48.5%, n = 98). Patients sex was associated with anti-HBs concentration (non-responders; poor responders; good responders), where significantly higher proportion of good responders were females compared to males ( = 0.007). In conclusion, HBV vaccine is efficient to elicit humoral immune response in hemodialysis patients.
乙型肝炎病毒（HBV）感染是一个全球性的健康问题。我们在本研究中的目的是调查麦地那地区完成乙肝疫苗接种系列后所产生的体液免疫反应。本横断面研究纳入了202名沙特血液透析（HD）患者。接受两次疫苗接种的患者中，乙肝表面抗体（抗-HBs）的平均浓度显著高于仅在开始血液透析后才接种疫苗的患者（分别为252±489 mIU/mL和144±327 mIU/mL，P = 0.008）。几乎一半的研究样本没有受到保护，抗-HBs浓度<10 mIU/mL。相比之下，20.3%（n = 41）被确定为低应答者（10 - 100 mIU/mL），只有28.2%（n = 57）被确定为高应答者（>100 mIU/mL）。然而，后两组被视为受到保护（48.5%，n = 98）。患者性别与抗-HBs浓度相关（无应答者；低应答者；高应答者），其中高应答者中女性的比例显著高于男性（P = 0.007）。总之，乙肝疫苗在血液透析患者中能有效引发体液免疫反应。
